ChemicalBook >  Product Catalog >  API >  Hormones and the Endocrine System >  Pancreatic hormone and blood sugar regulation >  Voglibose

Voglibose

Basic information Oral hypoglycemic agents Side Effects Uses Safety Related Supplier

Voglibose Basic information

Product Name:
Voglibose
CAS:
83480-29-9
MF:
C10H21NO7
MW:
267.28
EINECS:
1312995-182-4
Mol File:
83480-29-9.mol
More
Less

Voglibose Chemical Properties

Melting point:
162-163°C
alpha 
D25 +26.2° (c = 1 in water)
Boiling point:
601.9±55.0 °C(Predicted)
Density 
1.58±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
pka
13.26±0.70(Predicted)
Merck 
14,10029
InChIKey
FZNCGRZWXLXZSZ-CIQUZCHMSA-N
CAS DataBase Reference
83480-29-9(CAS DataBase Reference)
More
Less

Safety Information

Hazard Codes 
Xi
Risk Statements 
20/21/22-36/37/38
Safety Statements 
36/37-37/39-26
WGK Germany 
3
RTECS 
NM7524600
More
Less

Voglibose Usage And Synthesis

Oral hypoglycemic agents

Voglibose is an oral hypoglycemic agents which can alleviate the postprandial hyperglycemia of diabetes patients. It is first successfully developed by the Takeda Company in Japan. It belongs to α-glucosidase inhibitor (a drug which can delay the intestinal absorption of carbohydrates to achieve hypoglycemic effect). Its mechanism of action is through inhibiting the activity of disaccharides hydrolase (α-glucosidase) which can hydrolyze disaccharide into monosaccharide inside the gut and thus delaying the digestion and absorption of sugar and further alleviating the postprandial hyperglycemia. In the assay of measuring the exhaled hydrogen of healthy adults given sucrose loading, the results have confirmed that this drug in its clinical dosage has an inhibitory effect on hyperglycemia. When normal rats are subject to oral administration, this product can inhibit the increased blood sugar level after the increased loading of starch, sucrose, glucose and maltose, while it has no inhibitory effect on the increased blood sugar after increased loading of glucose, fructose, and lactose. In vitro analysis of mechanism of action have shown that, for the maltase and sucrose obtained from the small intestine of pig and rat, this drug has a strong inhibitory effect; on the other hand, it has a relative low inhibitory effect on the pancreatic α-amylase of pig and rat and has no inhibitory effect on β-glucosidase. It has a competitive inhibitory effect on the disaccharide hydrolase of the isomaltase-sucrase complex from the rat small intestine.
It is understood that voglibose has a broad scope of application; it is not only suitable for elderly patients with diabetes, but also has significant efficacy on patients with refractory type II diabetes, patients with secondary failure of sulfonylureas, patients with combined hyperlipidemia diabetes, patients with merged cardiovascular diabetes disease as well as patients with combined hyperinsulinemia. Because this product does not stimulate the secretion of insulin, it can reduce the harmful effects of postprandial hyperinsulinemia, reducing the resistance of insulin and contributes to the prevention and treatment of metabolic syndrome such as cardiovascular complications.

Side Effects

Mechanism of occurrence of side effects of oral administration of hypoglycemic agents is generally that: when the unabsorbed carbohydrate enters into the large intestine, under the action of bacteria, it subjects to glycolysis which produces carbon dioxide, hydrogen, and organic acids. At the same time, because of the increased osmotic pressure of intestinal, water retention happen which therefore causes increased exhausting, bloating, and diarrhea. Since voglibose can selectively inhibit the activity of the disaccharide hydrolase in the intestine, further delaying the rapid digestion and absorption of carbohydrate in the upper small intestine, and thus reducing saccharide, leading to a lower incidence of adverse reactions. It is known to have the following adverse reactions:
1. The digestive system: diarrhea, loose stools, borborygumus, abdominal pain, constipation, loss of appetite, nausea, vomiting, heartburn (incidence of 0.1 to 5%), stomatitis, thirst, abnormal taste, and pneumatosis cystoides gastrointestinalis (0.1%).
2. Allergic symptoms: rash, itching, light sensitivity (incidence of 0.1% or less).
3. Liver: GOT, GPT, LDH, γ-GTP, ALP are increased (0.1% incidence).
4. The nervous system: headache, dizziness, staggering, drowsiness (0.1% incidence).
5. The blood system: anemia (incidence of 0.1 to 5%), thrombocytopenia (0.1%).
6. Other: paralysis, facial swelling, hazy eyes, fever, flu, tiredness, feeling of fatigue, hyperkalemia, rise of serum amylase, decrease of high-density lipoprotein, sweating, hair loss (incidence of 0.1%).
The above information is edited by the chemicalbook of Dai Xiongfeng.

Uses

1. It is used for treating diabetes.
2. Anti-diabetic drug.

Description

Voglibose was introduced in Japan for the treatment of postprandial hyperglycemia in diabetic patients. As an orally active α-D-glucosidase inhibitor, it is effective in decreasing the release of glucose from carbohydrate ingestion and slowing the increase of postprandial blood glucose levels, as demonstrated in animals and humans following sucrose and starch loading. In addlion, voglibose was reported to have prophylactic effect in genetically obese Wistar rats, maintaining low plasma levels of glucose, triglyceride and insulin, indicating a potential usefulness for the management of other carbohydrate-dependent metabolic disorders such as obesity. Voglibose is much more potent and has fewer side effects than acarbose, another agent in its class.

Chemical Properties

Colourless Crystalline Solid

Originator

Takeda (Japan)

Uses

An alpha-Glucosidase inhibitor used as an antidiabetic

Uses

An α-Glucosidase inhibitor used as an antidiabetic.

Uses

For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.

brand name

Basen (Takeda); Glustat (Takeda).

World Health Organization (WHO)

Acarbose and voglibose area-glucosidase inhibitors and delay digestion/absorption of carbohydrates as well as improving postprandial hyperglycaemia.

Biological Activity

Orally active α -glucosidase inhibitor (IC 50 values are 3.9 and 6.4 nM at sucrase and maltase respectively). Increases glucagon-like peptide 1 (GLP-1) secretion and decreases food consumption in ob/ob mice, and reduces plasma concentrations of glucose, triglycerides and insulin in Wistar fatty rats. Exhibits antidiabetic and antiobesity activity in vivo .

More
Less

VogliboseSupplierMore

Beijing Union Pharm Gold
Tel:
010-63311281
Email:
cathyzhg@126.com
Hefei HomeSunshine Pharmaceutical Technology Co., Ltd. Gold
Tel:
0551-65523315
Email:
errol@homesunshinepharma.com
Shanghai finete Pharmaceutical Co., Ltd. Gold
Tel:
18221039705
Email:
finetechpharm@126.com
Shanghai Genriver Pharmaceutical Co., Ltd. Gold
Tel:
13482015261
Email:
info@genriverpharm.com
Wuxi Fuze Pharmaceutical Co., Ltd. Gold
Tel:
0510-83594580
Email:
sales@further-pharm.com
Basic information Oral hypoglycemic agents Side Effects Uses Safety Related Supplier